The scientific method is underpinned by hypotheses, and these are often tested in a study that includes a comparison of groups. In most instances an inferential statistical test is applied and a decision is then made to accept or reject the null hypothesis. In clinical research a statistically significant result leads the investigator(s) to conclude that one treatment is superior to another; most often this is the new treatment being superior to the comparator (control). But we ought to remember that a P value, of itself, does not tell us the probability of this being a true finding 1 . The P value is the probability that a difference as large as or larger than that observed is due to chance if the null hypothesis were true. A nonsignificant result, typically defined as P ≥0.05, is often misinterpreted as evidence of no effect, but this is incorrect -it simply means there is no evidence of effect 2 . A nonsignificant result therefore does not demonstrate equivalence [2] [3] [4] [5] [6] .
Clinicians are often interested in whether a new treatment is comparable to an existing treatment, particularly when the new treatment is considered safer, cheaper or easier to administer. They thus may not need to know the new treatment is superior, only that it be equivalent or at least as good as -noninferior to -the existing treatment [5] [6] [7] . A comparison that includes the possibility of better or equivalent outcomes provides an option to do a one-sided statistical test, and this reduces the necessary sample size required 3, 6, 7 . Such a noninferiority design is becoming increasingly popular in clinical research 8,9 . Placebo-controlled trials can be unethical if an existing treatment is known to be effective. It is more difficult to demonstrate a difference between two active groups, as opposed to an active group and placebo, because the expected effect size will be smaller. A smaller effect size leads to a requirement to study many more patients -that is, increased sample size -to ensure adequate study power. Noninferiority trials, because they use a one-sided statistical comparison, can minimise the requirement to increase the sample size when comparing two active treatment groups 6 .
For both equivalence and noninferiority trials, the first step is to determine what difference between groups could be considered trivial or of no clinically importance. This decision is best informed by expert clinical judgment, but the decision can be made more objective by using pooled data from previous studies. The chosen effect size is the prespecified delta (Δ); it is the difference beyond which we would conclude the new treatment is inferior. If the difference between groups is within the delta boundary then the groups can be accepted as equivalent 6, 10 . This determination must be made Equivalence and noninferiority in anaesthesia research Anaesth Intensive Care 2010; 38: 621-622 Figure 1 : Interpretation of noninferiority trials: the square and error bars indicate the estimated treatment difference and its 95% confidence interval (CI). In a noninferiority trial the delta (Δ) indicates the lower limit of difference that would be considered clinically equivalent. If the 95% CI exceeds Δ, then it remains likely that the true difference may be inferior to that of the existing treatment, and so noninferiority has not been demonstrated.
with added consideration of the likely range of the estimate of the true difference. This is done by using the 95% confidence interval (CI) of the treatment difference, and if this interval does not include the delta value, then it can be concluded that the groups are equivalent [9] [10] [11] . A noninferiority trial is handled in a similar fashion, whereby if the lower limit of the 95% CI lies within the noninferiority margin, it can be concluded that the new treatment is noninferior to the standard treatment ( Figure 1) . The interpretation of P values and the 95% CI derived from noninferiority or equivalence trials have been addressed 10 . If the range of the 95% CI includes both zero (no difference) and delta (inferiority), then the trial is inconclusive -the groups cannot be interpreted as equivalent. In this case there is insufficient evidence to claim noninferiority.
Noninferiority trials provide clinicians with useful information, and can be more efficient in that they lessen the sample size required -we often want to know whether a new treatment is at least as good as an existing treatment, not necessarily superior. If this is so, and the treatment is cheaper, safer or easier to administer, we can confidently adopt the new treatment knowing our patients should not come to any unintended harm. Noninferiority trials can often address the questions facing clinicians in their everyday practice. This innovation in trial design had adapted to the needs of clinical practicethe dog is back to wagging the tail.
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